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Abstract
Purpose The combination of hepatitis B immunoglobulin
(HBIg) and nucleos(t)ide analogues has been accepted as
the best treatment to control hepatitis B recurrence after
orthotopic liver transplantation (OLT). However, the opti-
mal dose of HBIg remains unclear. We have previously
reported that high-dose HBIg in the early period followed
by low-dose HBIg with nucleos(t)ide analogues offers
reliable and cost-effective control of hepatitis B recurrence.
The aim of this study was to investigate intrahepatic hep-
atitis B virus (HBV) reinfection status with our clinically
successful protocol.
Methods We quantiﬁed levels of intrahepatic HBV cova-
lently closed circular (ccc) deoxyribonucleic acid (DNA)
and serum hepatitis B core-related antigen (HBcrAg), a new
serological marker that can estimate intrahepatic cccDNA
levels. Nucleos(t)ide analogues were administered in all
cases.
Results No patients showed recurrence of hepatitis B
surface antigen (HBsAg) or HBV-DNA. However, HBV,
cccDNA, and HBcrAg were positive in 57% and 48% of
patients after OLT, respectively. Pre-OLT serum HBV-
DNA and HBcrAg levels correlated linearly with post-OLT
cccDNA levels (r = 0.534, P\0.05, and r = 0.634,
P\0.05, respectively). High serum HBV-DNA and
HBcrAg levels, particularly with[3 log10 copies/mL and
[4 log10 IU/mL, respectively, at the time of OLT, were
associated with high levels of post-OLT cccDNA. Even
with our successful protocol, nearly half of patients showed
HBV reinfection.
Conclusions Patients with high serum HBV-DNA and
HBcrAg levels before OLT (particularly [3 log10 copies/
mL and[4 log10 IU/mL, respectively) should be followed
with care for HBV recurrence.
Keywords Hepatitis B virus   Liver transplantation  
Recurrence   HBcrAg   HBV cccDNA
Introduction
Prior to the advent of effective post-transplantation anti-
viral prophylaxis, liver transplantation for hepatitis B virus
(HBV)-related disease was usually followed by immediate
HBV reinfection of the allograft, resulting in clinical hep-
atitis B recurrence conﬁrmed by positive results for serum
hepatitis B surface antigen (HBsAg) and/or HBV-DNA
(deoxyribonucleic acid) [1–3]. Recent studies have found
that the combination of hepatitis B immunoglobulin (HBIg)
and nucleos(t)ide analogues decreases the risk of HBV
recurrence and achieves a higher rate of graft survival [4–8].
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hepatitis B surface antibody (HBsAb) remain unclear. A
proposal for guidelines by Roche and Samuel [9] showed
that patients with HBV-DNA-positive status before ortho-
topic liver transplantation (OLT) need to maintain an anti-
HBs titer of 500 IU/L with concomitant use of lamivudine
(LAM). However, long-term administration of HBIg is
associated with several unresolved issues, including limited
availability and extremely high cost, so several arrange-
ments have been reported [8, 10–12]. Low-dose HBIg
resulting in a median HBsAb titer of 68 IU/L and combi-
nation with high-dose LAM at 300 mg/day has prevented
HBsAg recurrence in 96% of cases [12]. Low-dose HBIg
administration only when HBsAb titers dropped to\70 IU/
L combined with LAM at 100 mg/day has completely pre-
vented HBsAg recurrence [11]. We have already reported
that high-dose HBIg in the early period followed by low-
dose HBIg with nucleos(t)ide analogues offers reliable,
cost-effective control of hepatitis B recurrence [13].
Naı ¨ve hepatocytes could be infected by virus release
from extrahepatic sites, including the serum. Even after
10 years of successful clinical viral control post-OLT,
more than half of patients were reportedly reinfected with
the virus as conﬁrmed by HBV covalently closed circular
(ccc) DNA positivity of liver biopsy specimens [14]. The
risk of clinical HBV recurrence reportedly correlates with
high serum viral load pre-OLT. However, rates of rein-
fection to engrafted hepatocytes and correlations between
reinfection and clinical recurrence rates are not well doc-
umented. Few reports have conﬁrmed the existence of post-
OLT HBV cccDNA, the intrahepatic HBV replication
intermediate in infected hepatocytes.
A new assay has recently been developed for detecting
hepatitis B core-related antigen (HBcrAg), consisting of
HBV core antigen (HBcAg), HBV e antigen (HBeAg), and
a 22-kDa precore protein (p22cr) coded by the precore/core
gene [15, 16]. HBcrAg has been reported as a serum
marker that could estimate intrahepatic HBV cccDNA [17].
To investigate intrahepatic HBV reinfection status with
the clinically successful therapy of short-term high-dose
HBIg followed by long-term low-dose HBIg and nucle-
os(t)ide analogues therapy, we quantiﬁed intrahepatic HBV
cccDNA and serum HBcrAg.
Materials and methods
Patients and samples
From October 1996 to February 2009, living donor liver
transplantation (LDLT) was performed in 206 patients at
Okayama University Hospital. Of these, 34 cases showed
HBV-related liver cirrhosis. The overall actual survival rate
of patients is shown in Fig. 1. Five-year survival rates were
85% and 84% for all patients and for patients with HBV-
related liver cirrhosis, respectively.
Our HBV prophylaxis protocol was as follows. We
administered HBIg at 200 IU/kg intraoperatively. Former
patients received the same dose for an additional 1 week
postoperatively. HBIg was thereafter administered once
only at 2,000 IU for HBsAb titers \100 IU/L. After
6 months, HBIg was administered only for HBsAb titers
\10 IU/L. We measured HBsAg and HBsAb and/or HBV-
DNA every month for 6 months after LDLT and every
2–3 months thereafter. Two of the 34 HBV-related LDLT
patients dropped out from our HBV prophylaxis protocol
and were thus excluded from this study. The general
characteristics of patients included in this study are sum-
marized in Table 1. Patients were treated using a standard
immunosuppressive regimen (tacrolimus or cyclosporine A
and azathioprine or mycophenolate mofetil with steroids)
and nucleos(t)ide analogues were administered to all
patients. Nucleos(t)ide analogues were started a minimum
of 1 month preoperatively, as possible.
Serum samples and explanted liver and biopsy speci-
mens were obtained from these patients at our hospital after
obtaining informed consent. Explanted liver samples were
obtained from 12 patients. We performed protocol biopsies
at 1, 3, and 5 years after OLT. We explained the necessity
of routine liver biopsy to all patients after LDLT, but 19 of
the 32 patients did not agree and biopsy specimens were
thus obtained from 13 patients. All serum samples were
stored at -80C until analysis.
All study protocols were approved by the Ethics Com-
mittee at the Okayama University Hospital.
Routine laboratory tests
HBsAg, HBeAg, HBsAb, and HBeAb were routinely mea-
sured using a commercially available chemiluminescent
Fig. 1 Survival curve. Post-OLT survival of patients with LC(B) was
comparable to that of all patients. LC(B), type B liver cirrhosis
Hepatol Int (2011) 5:918–926 919
123enzyme immunoassay (CLEIA) system (Lumipulse System;
Fujirebio, Tokyo, Japan).
Serum HBcrAg assay
Serum HBcrAg was retrospectively measured using a
CLEIA HBcrAg assay kit (Fujirebio) with a fully automated
analyzer system (Lumipulse System, Fujirebio). Brieﬂy,
serum was mixed with pretreatment solution containing
sodium dodecylsulfate and Tween 60, then incubated at
60C for 30 min. This pretreated serum was added to a well
coated with monoclonal antibodies against denatured HBc
and HBe antigens. After 10 min of incubation at 37C,
wells were washed with buffer. Alkaline phosphatase-
labeled monoclonal antibodies against denatured HBc and
HBe antigens were added to the well and incubated for
10 min at 37C. After washing, substrate solution was
added and incubated for 5 min at 37C. Relative chemilu-
minescence intensity was measured at 477 nm, and the
HBcrAg concentration was determined [15].
Serum HBV-DNA assay
HBV-DNA level was measured using a transcription-
mediated ampliﬁcation assay (TMA) (SRL, Tokyo, Japan),
polymerase chain reaction (PCR) assay (Amplicor HBV
Monitor assay; Roche Diagnostics, Tokyo, Japan) or real-
time PCR assay (COBAS TaqMan HBV Test; Roche
Diagnostics).
Measurement of intrahepatic HBV cccDNA
and b-globin levels
Liver biopsy specimens were immediately divided into two
aliquots. One was formalin ﬁxed for histological diagnosis,
and the other was frozen within one minute for DNA
analysis. The aliquot for DNA analysis was stored at
-80C until DNA extraction. HBV-DNA was extracted
using a QIAamp DNA Mini Kit (Qiagen, Tokyo, Japan).
Intrahepatic cccDNA was retrospectively measured using
real-time PCR methods, as described previously [17]. To
detect cccDNA, two oligonucleotide primers of HBVccc
F1547 (50-ccccgtctgtgccttctc-30, nucleotides 1,547–1,564)
and HBVcccR1863 (50-gcacagcttggaggcttgaa-30, nucleotides
1,882–1,863), and the probe cccP2 (50-VIC-accaatttatgcct
acag-MGB-30, nucleotides 1,672–1,655) were administered,
as described previously, with minor modiﬁcation [17].
Selective primers for cccDNA ampliﬁcation were targeted
acrossthe single-strandedgapregionofrelaxedcircular(RC)
HBV-DNA.Toenhancethe speciﬁcityofcccDNA detection,
Table 1 General characteristics of patients
Total With explanted liver
Patients 32 12
Age (years)
a 51.5 (26–63) 52.5 (44–63)
Gender (male/female) 29/3 11/1
Hepatitis virus, HBV/HBV ? HCV 30/2 12/0
Hepatic malignancy 17 7
Donor anti-HBc status (positive/negative) 13/19 7/5
Antiviral prescription pre-OLT
n (%) 32 (100) 12 (100)
Duration (days)
a 56 (3–1,793) 163.5 (5–1,793)
Lamivudine/lamivudine ? adefovir/entecavir 25/4/3 8/2/2
Characteristics at OLT
Serum HBV-DNA: detectable (%) 57 42
HBV-DNA level in detectable cases (log10 copies/mL)
a 4.1 (2.7–5.5) 3.5 (2.7–4.8)
HBV genotype (C/not analyzed) 20/12 9/3
HBeAg status (positive/negative) 15/17 4/8
Immunosuppressant (tacrolimus/cyclosporine A) 26/6 11/1
Duration of post-OLT follow-up (months)
a 38 (2–103) 35 (4–53)
Recurrence (presence of serum HBsAg/hepatitis) 0/0 0/0
Post-OLT reinfection with HBV was deﬁned as positivity for any of the following HBV markers: serum HBsAg, serum HBcrAg, serum HBV-
DNA, or intrahepatic HBV cccDNA
DNA deoxyribonucleic acid, anti-HBc antibody to hepatitis B core antigen, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen, HBV
hepatitis B virus, HCV hepatitis C virus, OLT orthotopic liver transplantation
a Median (range)
920 Hepatol Int (2011) 5:918–926
123plasmid-safe DNase (Epicentre, Madison, WI, USA) was
used to degrade RC and single-stranded forms of viral DNA
prior to PCR. Plasmid-safe DNase treatment of virion-asso-
ciated DNA prevented ampliﬁcation, conﬁrming that this
DNase degraded RC forms of HBV-DNA [18].
Real-time PCR was performed in a Light-Cycler (Roche
Diagnostics). Cycling conditions of the assay were as fol-
lows: an initial 10 min at 95C for DNA polymerase
activation, followed by 45 cycles of 15 s denaturation at
95C, and 90 s annealing and extension at 60C. A 20-lL
reaction volume containing 5 lL of extracted nucleic acid,
0.12 lmol/L of forward and reverse primers, 0.10 lmol/L
of probe and 10 lL of LightCycler480 Probes Mater
(Roche Diagnostics) was administered. Serial dilutions of a
plasmid containing HBV-DNA extracted and cloned from
the serum of a 36-year-old Japanese woman (genotype C)
served as quantiﬁcation standards. HBV cccDNA values
were normalized for cellular DNA content using a com-
mercially available b-globin gene kit (Roche DNA Control
Kit; Roche Diagnostics).
The lower limit of detection for the HBV cccDNA was
-4 log10 copies/cell.
Immunohistochemical staining
Immunohistochemical staining was performed on sections of
ﬁxed liver tissues using a three-step horseradish peroxidase
technique. The primary monoclonal antibodies employed
were anti-HBsAg and anti-HBcAg (Dako, Tokyo, Japan).
Statistical analysis
Statistical comparisons were performed using JMP version
7.0.1 (SAS Institute, Cary, NC, USA). For nonparametric
pair-wise comparisons, the Spearman rank correlation
coefﬁcient was used, and the Wilcoxon rank sum test was
used for two-group comparisons. A value of P\0.05 was
considered signiﬁcant. All statistical tests were two-sided.
We performed per protocol analysis.
Results
Clinical course of patients
The 32 patients investigated comprised of 15 HBeAg-
positive and 17 HBeAg-negative patients (Table 1). Mean
duration of follow-up was 1,150.5 ± 869.8 days (range
61–3,090 days) after OLT. No patient showed recurrence
of serum HBsAg or serum HBV-DNA with real-time PCR
assay (Fig. 2). After 6 months postoperatively, HBIg was
used only 0.24 times/month, representing once every
4 months.
Explanted liver samples were obtained from 12 of the 32
patients, including 4 HBeAg-positive and 8 HBeAg-nega-
tive patients (Table 1). Serum HBV-DNA was detectable
in ﬁve patients (42%), with a median HBV-DNA level of
3.5 log10 copies/mL. Seven patients showed malignant
hepatic tumor. All 12 patients received pre-OLT antiviral
therapy for a median duration of 163.5 days. Mean follow-
up was 1,051 ± 416 days (range 115–1,576 days) after
OLT.
HBV viral status at the time of OLT
Serum HBV-DNA levels and serum HBcrAg at the time
of OLT were positively correlated (r = 0.461, P\0.05)
(Fig. 3a). HBV cccDNA was detected in 11 patients
(83%), with median HBV cccDNA levels of -0.77 log10
copies/cell. A signiﬁcant positive correlation was observed
between explanted liver cccDNA and serum HBV-DNA
(r = 0.760, P\0.005) (Fig. 3b). Although 6 of 12
patients from whom explanted livers were obtained were
serum HBV-DNA negative at OLT, 5 of those 6 patients
were positive for serum HBcrAg and intrahepatic HBV
cccDNA.
Time course of serum HBcrAg, intrahepatic HBV
cccDNA and intrahepatic HBsAg/HBcAg
A total of 13 patients with 14 biopsies collected between 11
and 74 months post-OLT were studied (Table 2). After
OLT, median serum HBcrAg decreased from 4.78
log10 IU/mL to undetectable (P\0.0001) (Fig. 4a). Seven
biopsy specimens showed no detectable HBV cccDNA.
The median concentration of HBV cccDNA was -3.19
log10 copies/cell. Median cccDNA decreased from -0.77
to -3.19 log10 copies/cell. This equates to a -0.77 log10
Fig. 2 Serum HBV-DNA titer pre- and post-OLT. No patients
showed recurrence of serum HBV-DNA with real-time PCR assay.
LLoD lower limit of detection
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123decrease (P\0.005) in cccDNA levels achieved after
OLT (Fig. 4b).
Serum HBcrAg was detectable in 48% of patients (10/
21) after 1,252 days post-OLT. Intrahepatic HBV cccDNA
was positive in 57% of patients (8/14) after 670.5 days
post-OLT (Fig. 4c).
HBsAg/HBcAg immunohistochemical staining was
studied in the 14 biopsied liver specimens. All samples
were negative for HBsAg/HBcAg immunohistochemical
staining.
Correlation between pre-OLT serum HBV-DNA
and post-OLT HBcrAg, intrahepatic HBV cccDNA
No signiﬁcant correlation was identiﬁed between pre-OLT
serum HBV-DNA and post-OLT serum HBcrAg (Fig. 5a).
A linear correlation was apparent between serum levels of
HBV-DNA at the time of OLT and post-OLT cccDNA
(r = 0.534, P\0.05) (Fig. 5b). All eight patients (100%)
with serum HBV-DNA\3 log10 copies/mL at the time of
OLT showed lower than -2 log10 copies/cell of HBV
cccDNA at post-OLT, while patients with pre-OLT serum
HBV-DNA [3 log10 copies/mL showed a signiﬁcantly
higher rate of post-OLT cccDNA higher than -2 log10
copies/cell (P\0.003) (Fig. 5c).
Correlation between pre-OLT HBcrAg and post-OLT
HBcrAg and intrahepatic HBV cccDNA
No signiﬁcant correlation was found between pre-OLT
HBcrAg and post-OLT serum HBcrAg (Fig. 6a). However,
a linear correlation was observed between HBcrAg at the
time of OLT and post-OLT cccDNA (r = 0.634, P\0.05)
(Fig. 6b). All six patients (100%) with HBcrAg [4 log10
IU/mL at the time of OLT showed detectable HBV
cccDNA post-OLT, while patients with pre-OLT HBcrAg
\4 log10 IU/mL showed a signiﬁcantly lower rate (14%)
of detectable cccDNA post-OLT (P\0.001) (Fig. 6c).
Age at OLT, gender, HCC at OLT, HBeAg status at
OLT, donor anti-HBc status, follow-up duration, immu-
nosuppressive agents, antiviral agents, and duration of
antiviral agent administration showed no effect on intra-
hepatic levels of cccDNA after OLT.
Discussion
This study found that even under clinically successful HBV
control post-OLT, serum HBcrAg and intrahepatic HBV
cccDNA were detectable in 48% and 57% of patients,
respectively. Pre-OLT high serum HBV-DNA titer could
predict post-OLT cccDNA level.
In 1991, Mu ¨ller et al. [19] reported the ﬁrst use of long-
term HBIg immunoprophylaxis, reducing recurrence rate
to 25% for 6 months and 18% for 12 months. In 1993,
Samuel et al. [20] reported a multicenter study in which the
3-year-risk of HBV recurrence was 75 ± 6% in patients
without HBIg, 74 ± 5% with short-term (2-month) HBIg
and 36 ± 4% with long-term ([6-month) HBIg treatment.
Patients who were positive for HBeAg or HBV-DNA dis-
played the greatest risk of recurrence (83%) and patients
with acute fulminant liver failure showed the lowest risk
(16%).
In 1996, Grellier et al. [21] reported a trial of LAM as a
prophylactic treatment achieving only 18% recurrence of
HBV by 6 months after OLT. However, the long-term
recurrence rate at 3 years after OLT had progressed to
41%, indicating that LAM monotherapy is not recom-
mendable for post-transplantation prophylaxis.
Although monotherapy with HBIg or LAM results in a
high rate of recurrence, a combination of these agents has
been administered with reasonable success. In 1998,
Markowitz et al. [22] reported no recurrences after 1 year
with combination therapy. Since HBIg is very expensive,
several reports have described modiﬁed combination ther-
apies. We have previously shown that long-term LAM with
short-term high-dose HBIg followed by low-dose HBIg
sufﬁcient to maintain HBsAb titer \10 IU/L is cost-
effective and powerful enough to control HBV recurrence
after LDLT. With this cost-saving method, no clinical
evidence of HBV recurrence has been seen. Intrahepatic
HBV cccDNA has been shown to be positive in 57% of
Fig. 3 Correlations between
HBV-related markers at the
time of OLT. Signiﬁcant
correlations were apparent
between: a serum HBcrAg and
serum HBV-DNA (r = 0.461,
P\0.05); and b intrahepatic
cccDNA and serum HBV-DNA
(r = 0.625, P\0.05)
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123Fig. 4 Time course of serum
HBcrAg (a), and intrahepatic
HBV cccDNA (b). Signiﬁcant
decreases were observed
(a P\0.0001, b P\0.005).
Serum HBcrAg was detectable
in 48% of patients after
1,252 days post-OLT.
Intrahepatic HBV cccDNA was
positive in 57% of patients at
670.5 days post-OLT (c)
Fig. 5 Correlation between
pre-OLT serum HBV-DNA and
post-OLT HBcrAg (a), and pre-
OLT serum HBV-DNA and
post-OLT HBV cccDNA (b). A
linear correlation was observed
in b (r = 0.534, P\0.05), but
not in a. All eight patients
(100%) with serum HBV-DNA
\3 log10 copies/mL at the time
of OLT showed post-OLT
cccDNA\2 log10 copies/cell,
signiﬁcantly higher than the rate
of 33% found in patients with
higher HBV-DNA levels (two
of six patients) (P\0.003) (c)
Fig. 6 Correlation between
pre-OLT HBcrAg and post-OLT
HBcrAg (a), and pre-OLT
HBcrAg and post-OLT HBV
cccDNA (b). A linear
correlation was observed in
b (r = 0.634, P\0.05), but not
in a. All six patients (100%)
with HBcrAg[4 log10 IU/mL
at the time of OLT showed
HBV cccDNA detectable at
post-OLT, while patients with
pre-OLT HBcrAg\4
log10 IU/mL showed a
signiﬁcantly higher rate of
undetectable cccDNA post-OLT
(P\0.001) (c)
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123patients. This would be comparable to the ﬁndings from
previous reports showing positive results for HBV cccDNA
post-OLT [23].
Intrahepatic HBV cccDNA could be detected in almost
all patients with HBV-related cirrhosis pre-OLT, although
all patients had received antiviral therapy pre-OLT and half
of the patients had undetectable serum HBV-DNA. Recent
studies have also shown that suppression of HBV-DNA in
serum does not indicate clearance of the virus from hepa-
tocytes [24], and the long half-life of cccDNA in reinfected
hepatocytes is responsible for viral recurrence following
OLT [19, 25–29]. Several reports have noted that high pre-
OLT serum HBV-DNA levels would predict HBV recur-
rence post-OLT [30, 31].
Our data indicate that higher pre-OLT serum HBV-
DNA levels and HBcrAg levels correlate with post-OLT
cccDNA levels. Even with our successful protocol, patients
with high pre-OLT serum HBV-DNA levels and HBcrAg
levels, particularly [3 log10 copies/mL and [4 log10 IU/
mL, respectively, should be followed with care for HBV
recurrence.
HBV is an enveloped DNA virus containing an RC
DNA genome, which is converted into a cccDNA in the
nucleus of infected cells. The cccDNA episome is the
transcriptional template for HBV messenger RNA tran-
scripts that encode viral structural and non-structural pro-
teins and the 3.5-kb pregenomic (pg) RNA template for
reverse transcription and synthesis of the viral genome. The
pg RNA serves as the template for reverse transcription to
generate viral DNA. Nucleos(t)ide analogues inhibit the
reverse transcription of pg RNA, and can thus rapidly
decrease serum levels of HBV-DNA, but cannot eliminate
the cccDNA reservoir. The cccDNA is thus recognized as a
putative marker for real HBV-DNA replication ability that
might suggest the suitable time to withdraw nucleos(t)ide
analogues. HBcrAg, representing a complex of HBeAg,
HBcAg, and p22cr, has been shown to correlate with
cccDNA [17]. HBcrAg would thus represent a good non-
invasive marker to recognize intrahepatic HBV replication
status. The present data show positive results for HBcrAg
as frequently as for intrahepatic HBV cccDNA (Fig. 4).
Although evaluation for low titers of HBcrAg would be
difﬁcult (Fig. 5a), positive HBcrAg offers a good marker to
conﬁrm HBV reinfection after OLT. Even when serum
HBV-DNA is undetectable, patients at higher risk of HBV
recurrence can be differentiated from those at lower risk of
HBV recurrence who can be withdrawn from HBIg or
nucleos(t)ide analogues by high HBcrAg positivities.
In conclusion, long-term nucleos(t)ide analogues with
short-term high-dose HBIg followed by low-dose HBIg
supplementation only when the HBsAb titer falls below
10 IU/L is sufﬁcient to suppress intrahepatic HBV-DNA
replication and control HBV recurrence after OLT.
However, almost half of the patients were positive for
intrahepatic HBV cccDNA and serum HBcrAg, even
though titers were low. Patients with high pre-OLT serum
HBV-DNA levels, high pre-OLT HBcrAg levels, and
positive post-OLT results for HBcrAg should be carefully
followed to identify patients who might show HBV
recurrence.
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